AbCellera Biologics Quarterly Income Statement
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AbCellera Biologics revenue and earnings
In the quarter ended Jun 30, 2026, AbCellera Biologics generated $4.0 million in revenue, down 76.3% from the same quarter a year earlier. AbCellera Biologics reported a net loss of $55.4 million, compared with a loss of $34.7 million a year earlier. Operating margin was -1550.0%.
Diluted earnings per share came in at -$0.18.
Summary generated from market data by MetaCap's automated system. Methodology
AbCellera Biologics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.05M | 8.31M | 44.85M | 8.96M | 17.08M | 4.24M | 5.05M | 6.51M | 7.32M | 9.95M | 9.18M | 6.60M |
| Revenue growth (YoY) | -76.29% | +96.34% | +788.18% | +37.62% | +133.29% | -57.45% | -44.98% | -1.39% | -27.18% | -18.36% | -57.40% | -93.49% |
| Operating Expenses | 66.83M | 65.83M | 73.44M | 85.23M | 66.67M | 66.89M | 77.81M | 100.17M | 100.78M | 64.85M | 75.23M | 61.49M |
| Research & Development | 45.99M | 46.66M | 50.09M | 55.03M | 39.21M | 42.50M | 46.08M | 40.97M | 40.93M | 39.29M | 48.62M | 37.92M |
| Selling, General & Admin | 13.85M | 12.33M | — | 24.96M | 21.99M | 19.07M | 31.94M | 22.28M | 23.33M | 20.72M | 33.25M | 17.84M |
| Operating Income | -62.78M | -57.52M | -28.58M | -76.28M | -49.59M | -62.66M | -72.75M | -93.66M | -93.45M | -54.89M | -66.05M | -54.89M |
| Other Income (Expense) | 3.81M | 7.98M | 9.08M | 7.51M | 13.24M | 9.68M | 25.93M | 31.03M | 45.27M | 12.15M | 17.45M | 15.61M |
| Pretax Income | -58.97M | -49.54M | -19.50M | -68.77M | -36.34M | -52.98M | -46.83M | -62.63M | -48.19M | -42.75M | -48.60M | -39.28M |
| Income Tax | -3.54M | -6.37M | -10.55M | -11.65M | -1.62M | -7.36M | -12.62M | -11.53M | -11.26M | -2.14M | -1.45M | -10.67M |
| Net Income | -55.43M | -43.16M | -8.95M | -57.12M | -34.73M | -45.62M | -34.21M | -51.11M | -36.93M | -40.61M | -47.15M | -28.61M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -207.46% |
| EPS (Basic) | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 | -0.15 | -0.11 | -0.17 | -0.13 | -0.14 | -0.16 | -0.10 |
| EPS (Diluted) | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 | -0.15 | -0.11 | -0.17 | -0.13 | -0.14 | -0.16 | -0.10 |
| Shares Outstanding (Basic) | 305.56M | 303.07M | — | 298.88M | 298.51M | 297.69M | — | 294.85M | 294.22M | 292.72M | — | 289.50M |
| Shares Outstanding (Diluted) | 305.56M | 303.07M | — | 298.88M | 298.51M | 297.69M | — | 294.85M | 294.22M | 292.72M | — | 289.50M |
| EBITDA | -55.79M | -50.68M | -23.40M | -71.03M | -44.12M | -57.33M | -70.66M | -56.74M | -56.93M | -50.05M | -58.52M | -49.16M |
| Operating Margin | -1550.05% | -691.75% | -63.72% | -851.79% | -290.24% | -1479.57% | -1440.69% | -1439.42% | -1276.17% | -551.48% | -719.61% | -831.79% |
| Net Margin | -1368.57% | -519.12% | -19.94% | -637.84% | -203.27% | -1077.24% | -677.43% | -785.42% | -504.30% | -407.98% | -513.67% | -433.55% |
This table shows 12 quarterly periods of AbCellera Biologics's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ABCL's reporting calendar. What is a income statement?